Trial Profile
A Randomised, Double-Blind, Placebo Controlled, Multi-Center Study To Investigate The Use Of Mepolizumab (Sb-240563) In Reducing The Need For Surgery In Subjects With Severe Bilateral Nasal Polyposis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Nasal polyps
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 22 Dec 2014 Status changed from active, no longer recruiting to completed as reported by Clinical trial.gov record.
- 06 Nov 2014 Planned End Date changed from 1 Aug 2014 to 1 Nov 2014 as reported by Clinical trial.gov record.
- 21 Jun 2014 New trial record